In the face of the outbreak of the COVID-19,Deloitte launched an industry survey of 100 management from leading domestic and foreign pharmaceutical enterprises(the survey results were released on February 25).The survey shows that most enterprises have taken active measures to cope with the epidemic,but on the other hand,the spread of the epidemic has also exposed the urgent areas for improvement in China's medical system.The COVID-19 epidemic will accelerate the promotion of a patient-centered medical system and further emphasize the important role of community medical centers.

　　Jane Sihua,the leading partner of Deloitte China's life sciences and medical industry,said:"Affected by the COVID-19,enterprises will accelerate the market layout of digital technologies and solutions.In addition to taking specific response measures,the medical system will further strengthen epidemic prevention and monitoring,including the use of artificial intelligence diagnostic technologies and tools."

　　This epidemic will promote profound changes in China's medical industry,including increasing investment in disease prevention infrastructure,accelerating the digital transformation of medical service models,re examining the pipeline product layout strategy of pharmaceutical enterprises,and adopting advanced medical technology solutions.Deloitte made six predictions in the report and clarified the underlying meanings for industry participants.

　　Yu Chao,the leading partner of Deloitte China Life Sciences and Medical Industry Management Consulting,said:"In the long run,the outbreak of the COVID-19 will accelerate the transformation of China's medical system.I believe that when we look back many years later,we will find that many medical industry disruptors have emerged from this epidemic.Participants in the industry ecology must take precautions to seize the opportunity."